GLP-1 agonists around conception: no clear signal, no proof of safety

Design

Systematic review and meta-analysis of 10 observational studies

Population

2,118,215 women; 8,325 exposed to GLP-1 receptor agonists within 6 months before a positive pregnancy test

Primary outcome

Miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders, gestational diabetes, fetal growth and gestational weight gain

Effect

No clearly detectable increase in any; preeclampsia OR 0.87 (95% CI 0.78 to 0.98), two datasets

A systematic review pooled ten observational studies comparing pregnancies with and without GLP-1 receptor agonist exposure in the six months before a positive pregnancy test. In total 8,325 exposed and 2,109,890 unexposed women were included.

Pooled estimates did not show a clearly detectable increase in miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders, gestational diabetes, abnormal fetal growth or excess gestational weight gain. A lower estimate for preeclampsia appeared (OR 0.87, 95% CI 0.78 to 0.98), but it rested on only two datasets.

The authors are explicit that these findings do not establish safety. Heterogeneity, residual confounding and small exposed groups limit what can be said, and the congenital-anomaly sensitivity analysis reused the same four studies.

In clinic this matters because these drugs are increasingly taken by women of reproductive age. The data are reassuring enough to support an unhurried conversation after an unplanned conception, not a reason to treat continued exposure as settled.

• Ask every woman of reproductive age on a GLP-1 agonist about pregnancy intentions and contraception.
• After an unplanned conception on one, review the indication and discuss stopping, rather than assuming harm or safety.
• Pooled data showed no clearly detectable rise in miscarriage, anomalies or preterm birth, but exposed groups were small.
• The preeclampsia finding came from two datasets only; do not use it to justify exposure.

Why it matters

It replaces an assumption of harm with an uncertain but so far quiet signal, which changes how an unplanned exposure is discussed.

Don't overread it

The authors state that the findings do not establish safety; the preeclampsia estimate rests on two datasets.

The statistics, in plain English

A confidence interval that crosses 1.0 means the data are compatible with no difference. Most outcomes here did so. With only 8,325 exposed women, rare outcomes such as specific malformations could still be missed, and observational comparisons cannot fully remove differences between women who do and do not take these drugs.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.